Clinical Trial

The Impact of Acupuncture on Biomarkers of Brain Injury and Inflammatory Response in Migraine

Study acronym: ACUPMIGRAINE
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 18, 2025 (before its estimated March 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
Migraine is more than just a headache-it can involve changes in the brain and inflammation. Recent research suggests that acupuncture may help by calming pain signals and reducing inflammation in the body. Scientists are studying whether acupuncture can also lower certain markers in the blood that show brain stress or inflammation. While more research is needed, acupuncture is considered safe and may reduce the number and severity of migraine attacks for many people. Acupuncture has been used for over 40 years in our practice to manage acute and chronic pain, including migraines. When performed by trained physicians, it is safe and typically reduces headache frequency and intensity, as well as nausea and vomiting, lowering the need for pain medication. Investigators are exploring three different ways to help manage migraine headaches using gentle stimulation techniques. These include laser acupuncture, electroacupuncture, and traditional acupuncture. Investigators want to see which method works best for reducing migraine symptoms. Investigators will look at how participants feel after treatment and also check blood samples for signs of inflammation and certain substances linked to migraines, such as calcitonin gene-related peptide (CGRP) and markers of brain stress. Investigators have a goal to find safe and effective options that can improve migraine care and help people feel better.
Trial Details
NCT Number NCT07292506
Lead Sponsor University Medical Centre Ljubljana
Conditions Migraine, Migraine Headache, Migraine Headache, With or Without Aura, Migraine in Adults
Enrollment 75 participants
Start Date 2025-11-03
Primary Completion 2026-03-15 (estimated)
Study Completion 2026-07-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-18